 Amneal Pharmaceuticals Inc NYSE: AMRX reports Q2 revenue of 535 million, an increase of 15 YY, beating the consensus of 523.25 million. Sales growth was driven by Generic product launches, specialty products Rytary Unithroid, and overall volume growth within Generics and AvKARE segments. 